MedTrace Logo

A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy Participants

NCT05537090 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-11-21

No results posted yet for this study

Summary

To evaluate the effect of repeated doses of intravenous BV100 on the pharma-cokinetics of midazolam and 1-hydroxymidazolam.

Conditions

  • Healthy Volunteers

Interventions

DRUG

BV100

Rifabutin for Infusion

DRUG

Midazolam

Syrup for oral administration

Sponsors & Collaborators

  • Clinical Research Units Hungary

    collaborator OTHER

  • BioVersys AG

    lead INDUSTRY

Principal Investigators

  • Geza Lakner · Clinical Research Units Hungary

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2023-07-31
Completion
2023-09-30

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05537090 on ClinicalTrials.gov